Th e article presents clinical applications of the drug regorafenib (Stivarga) in patients with metastatic colorectal cancer. Consistent use of anticancer drugs, chemoembolization of the hepatic artery, resection of metastases and multikinase inhibitor of tyrosine kinase regorafenib with resistance to previously used schemes of anticancer therapy provides adequate control over the tumor in this category of patients. In this case it can be noticed the moderate manifestation of toxicity, which is important for earlier pretreated patients. Th e experience of regorafenib application demonstrates the possibility of its long-term use on the background of high effi ciency and controlled safety profi le.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.